查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994342

基因分析市场：按产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Genetic Analysis Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因分析市值将达到 117.3 亿美元，到 2026 年将成长到 125.9 亿美元，到 2032 年将达到 209.4 亿美元，复合年增长率为 8.62%。

主要市场统计数据
基准年 2025 117.3亿美元
预计年份：2026年 125.9亿美元
预测年份 2032 209.4亿美元
复合年增长率 (%) 8.62%

清楚概述了技术成熟度、监管变化和业务扩张如何重新定义基因分析领域所有相关人员的优先事项和策略选择。

在技​​术进步和医疗保健重点转变的推动下，基因分析领域正进入科学成熟和商业性化加速发展的阶段。近年来，定序处理能力显着提升，单一样本的处理时间大幅缩短。这使得更多临床和研究应用案例得以从探索阶段过渡到常规工作流程。同时，检查室自动化和基于云端的生物资讯学降低了规模化应用的门槛，使机构能够在保证品质和可重复性的前提下处理更多样本。

高通量技术的整合、监管对临床效用的重视以及供应链的韧性如何改变竞争动态和策略重点。

基因分析生态系统正在发生根本性转变，重塑价值创造的模式以及创新在整个价值链中的流动方式。高通量定序、先进的PCR技术和改进的微阵列平台等技术的融合，结合云原生分析技术，建构了一个整合的流程，缩短了周转时间，提高了诊断准确性。这使得检查室和商业供应商能够扩展其服务组合，并推行垂直整合策略，将仪器、耗材和资讯服务整合在一起。

了解关税制度的变化如何影响整个基因分析生态系统的筹资策略、供应商多元化和本地生产决策。

主要经济体关税政策的变化可能会对检查室、製造商和服务供应商的成本结构和采购决策产生重大影响。进口试剂、设备和特殊组件关税的提高可能会增加直接接收成本，并造成价格压力不均，从而扭曲国内外供应商之间的采购。为此，製造商可能会调整其全球筹资策略，将部分组装流程转移到更靠近需求中心的地方，或调整产品系列，优先考虑贸易条件有利的地区。

详细的細項分析揭示了技术模式、应用、产品类型和最终用户画像如何共同塑造商业性通路和投资重点。

从细分市场的观点来看，技术能力、客户需求和商业化模式的交会点清晰可见，从而创造了差异化的机会。技术细分突显了传统平台与新兴技术之间的互动。具体而言，微阵列在标靶基因型鉴定和人群研究中仍然发挥着重要作用；次世代定序(NGS) 推动了全面的基因组分析和新型应用；聚合酵素链锁反应(PCR) 支持快速诊断和定量分析；而桑格定序则继续为检验和特定定序任务做出贡献。每条技术路径都有其独特的开发週期、法规考量和成本绩效特征，这些因素都会影响其应用轨迹。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和独特机会正在影响战略市场进入和供应链选择。

全球基因分析市场的区域趋势造就了不同的机会与风险。在美洲，成熟的医疗基础设施和完善的报销机制为先进的临床应用、强劲的私人投资以及紧密的诊断检查室和生物製药合作伙伴网络提供了支持。这种环境有利于快速的临床应用和商业化规模化，同时也吸引了人才和资本投向仪器和软体相关的企业。

竞争格局洞察显示，平台创新、整合服务和符合监管规定的合作伙伴关係如何决定领导地位和差异化。

基因分析领域的竞争格局反映了技术领先地位、综合服务能力和策略伙伴关係关係的整合。领先的仪器製造商持续投资于提升处理能力、简化操作流程以及完善耗材生态系统，以确保市场需求的持续成长。同时，专业服务供应商和定序中心正通过认证、快速週转以及与临床级服务相结合的生物资讯深度，为医院和诊断检查室提供差异化优势。

为领导者提供切实可行的建议，以增强价值链韧性、加速临床检验、扩展分析能力并开发灵活的价值创造经营模式。

产业领导者应优先采取一系列切实可行且影响深远的措施，将策略意图转化为可衡量的成果。首先，实现关键试剂和组件供应商多元化，探索近岸外包和区域生产伙伴关係，以降低地缘政治和关税风险，并增强供应链韧性。其次，将产品开发与临床效用证据的取得结合。投资前瞻性检验试验，与保险公司合作，并简化报销流程，以加速产品推广应用。

我们高度透明的调查方法，结合了相关人员访谈、二手文献整合和基于情境的分析，得出检验的策略见解和可操作的指南。

本分析的调查方法融合了与关键相关人员的对话、对二手文献的回顾以及与监管和临床指南的交叉比检验，以确保获得可靠且可操作的见解。关键资讯来源包括与实验室经理、研发经理、采购负责人和生物资讯专家进行结构化访谈，以了解实际操作情况、推广应用障碍以及临床检验的优先事项。这些定性观点与近期同侪审查文献、监管公告和专利趋势的系统性回顾进行交叉比对，以检验技术进步和新兴应用案例。

结论强调，要充分发挥基因分析的潜力，必须将严谨的证据生成、强大的营运系统和以客户为中心的数位化能力结合。

总而言之，基因分析领域正处于强大的技术能力与复杂的商业性、监管和供应链现实的交汇点。定序、PCR 和自动化技术的进步使其在临床和研究领域广泛应用，但长期成功取决于能否证明其临床效用、确保供应的连续性以及应对不同的区域法规结构。那些能够整合高品质证据的创建、稳健的营运设计和以客户为中心的数位化工具的机构，将建立永续的竞争优势。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 基因分析市场：依产品类型划分

  • 消耗品
  • 装置
  • 服务
  • 软体

第九章 基因分析市场：依技术划分

  • 微阵列
  • 次世代定序
  • 聚合酵素链锁反应
  • 桑格定序

第十章 基因分析市场：依应用领域划分

  • 临床诊断
  • 遗传性疾病
  • 感染疾病
  • 肿瘤学
  • 生殖医学

第十一章 基因分析市场：依最终使用者划分

  • 合约研究机构
  • 诊断检测实验室
  • 医院
  • 製药公司
  • 研究机构

第十二章 基因分析市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 基因分析市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 基因分析市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国基因分析市场

第十六章：中国基因分析市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Beam Therapeutics Inc.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GenScript Biotech Corporation
  • Illumina, Inc.
  • Intellia Therapeutics, Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Sangamo Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-1A1A064C059E

The Genetic Analysis Market was valued at USD 11.73 billion in 2025 and is projected to grow to USD 12.59 billion in 2026, with a CAGR of 8.62%, reaching USD 20.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.73 billion
Estimated Year [2026] USD 12.59 billion
Forecast Year [2032] USD 20.94 billion
CAGR (%) 8.62%

An incisive overview of how technological maturation regulatory shifts and operational scaling are redefining priorities and strategic choices across genetic analysis stakeholders

The genetic analysis landscape has entered a period of accelerated scientific maturation and commercial evolution driven by converging technological advances and shifting healthcare priorities. Recent years have seen exponential improvements in sequencing throughput and reductions in per-sample processing time, enabling a wider set of clinical and research use cases to transition from exploratory stages into routine workflows. Concurrently, laboratory automation and cloud-enabled bioinformatics have lowered barriers to scale, giving institutions the ability to process higher volumes while maintaining quality and reproducibility.

These operational gains are complemented by a more nuanced regulatory environment that emphasizes analytical validity, clinical utility, and data governance. Stakeholders now operate within a context where ethical considerations, privacy frameworks, and payer expectations shape adoption pathways as strongly as raw technical capability. As a consequence, strategic choices around platform selection, partnership models, and talent development are increasingly defining competitive differentiation. Leaders who align investments with demonstrable clinical outcomes and robust compliance postures will be better positioned to capture long-term value.

How convergence of high-throughput technologies regulatory emphasis on clinical utility and supply chain resilience is shifting competitive dynamics and strategic priorities

Fundamental shifts in the genetic analysis ecosystem are remapping where value accrues and how innovation flows across the value chain. Technological convergence has brought together high-throughput sequencing, advanced PCR modalities, and improved microarray platforms with cloud-native analytics, creating integrated pipelines that reduce turnaround time and improve diagnostic resolution. This has enabled laboratories and commercial providers to expand service portfolios and pursue vertical integration strategies that combine instrumentation, consumables, and data services.

At the same time, payer scrutiny and outcome-based contracting are incentivizing the development of clinically actionable assays and companion diagnostics. As clinical utility takes center stage, companies are redirecting R&D investments toward indications with clear pathways to reimbursement and demonstrated patient benefit. Additionally, supply chain resilience has become a strategic imperative; disruptions and geopolitical forces have accelerated efforts to diversify sourcing, localize critical production, and build inventory and logistics flexibility. Together, these forces are transforming competitive dynamics and encouraging collaborations that span industry incumbents, academic centers, and specialist service providers.

Understanding how changes in tariff regimes influence procurement strategy supplier diversification and localized manufacturing decisions across the genetic analysis ecosystem

Tariff policy shifts in major economies can materially alter cost structures and procurement decisions across laboratories, manufacturers, and service providers. Increased tariffs on imported reagents, instruments, and specialized components raise direct landed costs and can create uneven pricing pressures that distort procurement between domestic and international suppliers. In response, manufacturers may reconfigure global sourcing strategies, relocate certain stages of assembly closer to demand centers, or adjust product portfolios to prioritize regions with favorable trade terms.

Operationally, laboratories and contract research providers respond to tariff-driven cost inflation by optimizing inventory management, renegotiating supplier contracts, and exploring alternative assay workflows that rely on more readily available inputs. Transitional periods following tariff implementation typically see cautious ordering behavior as buyers reassess total landed cost and evaluate the trade-offs between price, performance, and supply continuity. Regulatory considerations also intersect with tariff impacts when reagents or instruments require specific approvals; localized manufacturing can help mitigate both tariff exposure and approval lead times. Ultimately, while tariffs add a layer of complexity to procurement and pricing, organizations that proactively model supply chain scenarios and pursue supplier diversification can preserve continuity and maintain competitive pricing strategies.

In-depth segmentation analysis revealing how technology modalities applications product types and end-user profiles jointly shape commercial pathways and investment priorities

Segment-level perspectives reveal where capability, customer needs, and commercialization models intersect to create differentiated opportunities. Technology segmentation highlights the interplay between legacy platforms and emerging modalities, where Microarray remains relevant for targeted genotyping and population studies, Next Generation Sequencing drives comprehensive genomic profiling and novel applications, Polymerase Chain Reaction supports rapid diagnostics and quantitation, and Sanger Sequencing continues to serve validation and niche sequencing tasks. Each technology pathway presents distinct development cycles, regulatory considerations, and cost-performance characteristics that influence adoption trajectories.

Application segmentation shows how use cases shape product design and service delivery, with Clinical Diagnostics demanding validated workflows and reproducible analytics, Genetic Disease analyses requiring deep variant interpretation and counseling integration, Infectious Disease testing prioritizing speed and multiplexing, Oncology focusing on sensitivity for low-frequency variants and actionable biomarkers, and Reproductive Health emphasizing accuracy and ethical counseling. Product type segmentation clarifies business model implications: Consumables create recurring revenue and inventory planning complexities, Instruments involve capital expenditure and maintenance ecosystems, Services rely on operational scale and quality accreditation, and Software requires data integration, regulatory clarity, and ongoing algorithmic validation. End-user segmentation underscores the diversity of procurement and operational contexts, as Contract Research Organizations prioritize throughput and standardization, Diagnostic Laboratories focus on accreditation and clinical turnaround, Hospitals demand integration with care pathways, Pharmaceutical Companies emphasize translational research and companion diagnostics, and Research Institutes concentrate on experimental flexibility and methodological innovation. By tracing how these segment dimensions interact, stakeholders can target investments that align technical capabilities with the specific regulatory, operational, and commercial constraints of their customers.

Regional dynamics and differentiated opportunity sets across the Americas Europe Middle East & Africa and Asia-Pacific that determine strategic go-to-market and supply chain choices

Regional dynamics drive differentiated opportunity sets and risk profiles across the global genetic analysis landscape. In the Americas, mature healthcare infrastructure and established reimbursement mechanisms support advanced clinical applications, strong private investment, and a dense network of diagnostic laboratories and biopharma partners. This environment favors rapid clinical translation and commercial scale-up, while also attracting talent and capital for instrumentation and software ventures.

Across Europe, the Middle East & Africa, regulatory heterogeneity and diverse healthcare funding models create both challenges and niches for tailored solutions, with leading academic centers and specialized commercial providers advancing precision oncology and rare disease diagnostics. In the Asia-Pacific region, a combination of large population cohorts, expanding healthcare coverage, and growing domestic manufacturing capability has driven rapid adoption of both high-throughput sequencing and cost-effective PCR-based diagnostics. Regional policy incentives and local production initiatives further influence supply chain strategies, while cross-border collaborations and investment flows continue to intensify as stakeholders seek to address capacity, access, and localized clinical needs. Together, these regional characteristics require companies to adapt go-to-market strategies, regulatory approaches, and partnership models to capture opportunities effectively.

Competitive landscape insights showing how platform innovation integrated services and regulatory-aligned collaborations are determining leadership and differentiation

Competitive positioning across the genetic analysis space reflects a blend of technology leadership, integrated service capabilities, and strategic partnerships. Leading instrument manufacturers continue to invest in throughput improvements, ease of use, and consumables ecosystems that lock in recurring demand. At the same time, specialized service providers and sequencing hubs differentiate through accreditation, fast turnaround, and bioinformatics depth that translate into clinical-grade offerings for hospitals and diagnostic laboratories.

Software and algorithm developers are increasingly important as interpretation complexity grows; robust variant curation, machine learning-driven prioritization, and secure data management now sit at the core of clinical adoption. Collaborative models are also prominent, as pharmaceutical companies, academic centers, and diagnostics firms form consortia to share data and accelerate assay validation for complex indications. For organizations evaluating competitive moves, the emphasis should be on securing clinical validation pathways, establishing durable supply chains for critical consumables, and forging alliances that combine technical capabilities with market access. Those that balance platform innovation with service excellence and regulatory rigor will sustain competitive advantage.

Actionable recommendations for leaders to strengthen supply chain resilience accelerate clinical validation expand analytics capabilities and deploy flexible commercial models to capture value

Industry leaders should prioritize a set of pragmatic, high-impact actions to translate strategic intent into measurable outcomes. First, strengthen supply chain resilience by diversifying suppliers for critical reagents and components and by assessing nearshoring or regional production partnerships to reduce geopolitical and tariff exposure. Second, align product development with evidence generation that demonstrates clinical utility; invest in prospective validation studies and payer engagement to streamline reimbursement pathways and accelerate adoption.

Third, expand analytics and software capabilities to deliver clinically meaningful interpretation and seamless integration with electronic health records and laboratory information systems; this will enhance customer retention and unlock higher-value service contracts. Fourth, pursue targeted collaborations with healthcare systems and research centers to co-develop assays that meet real-world needs, thereby reducing market entry friction. Finally, build flexible commercial models that combine instrument leasing, consumable subscriptions, and outcome-based contracting to address diverse customer procurement preferences and to create predictable revenue streams. Executing these recommendations will require cross-functional governance, clear KPIs tied to clinical uptake, and investment in talent capable of navigating both regulatory and commercial complexities.

Transparent research methodology combining stakeholder interviews secondary literature synthesis and scenario-based analysis to produce validated strategic insights and actionable guidance

The research methodology underlying this analysis synthesizes primary stakeholder engagement, secondary literature review, and cross-validation with regulatory and clinical guidance to ensure robust, actionable insights. Primary input included structured interviews with laboratory directors, R&D leaders, procurement officers, and bioinformatics specialists to capture operational realities, adoption barriers, and priorities for clinical validation. These qualitative perspectives were triangulated with a systematic review of recent peer-reviewed literature, regulatory agency communications, and patent activity to verify technological trajectories and emergent use cases.

Analytical rigor was maintained through scenario-based supply chain modeling and comparative assessment of platform capabilities against clinical requirements for sensitivity, specificity, throughput, and cost per assay. Interpretative layers considered reimbursement pathways and accreditation constraints to ensure recommendations align with real-world adoption levers. Throughout the process, findings were stress-tested for plausibility and operational feasibility, while confidentiality and respondent anonymity were strictly maintained to encourage candid input from industry participants.

Concluding synthesis emphasizing the necessity of combining rigorous evidence generation resilient operations and customer-centric digital capabilities to realize the promise of genetic analysis

In synthesis, the genetic analysis domain is at the intersection of powerful technological capability and complex commercial, regulatory, and supply chain realities. Advances in sequencing, PCR, and automation have unlocked broader clinical and research applications, but long-term success hinges on demonstrating clinical utility, ensuring supply continuity, and navigating diverse regional regulatory frameworks. Organizations that integrate high-quality evidence generation with resilient operational design and customer-focused digital tools will establish durable competitive positions.

Looking ahead, the most successful players will be those that balance innovation with pragmatic execution: investing in validation studies that speak to payers and clinicians, building modular service offerings that adapt to varied end-user needs, and cultivating partnerships that bridge technical expertise with market access. By doing so, stakeholders can translate scientific promise into measurable patient impact and sustainable commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genetic Analysis Market, by Product Type

  • 8.1. Consumables
  • 8.2. Instruments
  • 8.3. Services
  • 8.4. Software

9. Genetic Analysis Market, by Technology

  • 9.1. Microarray
  • 9.2. Next Generation Sequencing
  • 9.3. Polymerase Chain Reaction
  • 9.4. Sanger Sequencing

10. Genetic Analysis Market, by Application

  • 10.1. Clinical Diagnostics
  • 10.2. Genetic Disease
  • 10.3. Infectious Disease
  • 10.4. Oncology
  • 10.5. Reproductive Health

11. Genetic Analysis Market, by End User

  • 11.1. Contract Research Organizations
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Pharmaceutical Companies
  • 11.5. Research Institutes

12. Genetic Analysis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Genetic Analysis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Genetic Analysis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Genetic Analysis Market

16. China Genetic Analysis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Beam Therapeutics Inc.
  • 17.7. BGI Group
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. CRISPR Therapeutics AG
  • 17.10. Danaher Corporation
  • 17.11. Editas Medicine, Inc.
  • 17.12. F. Hoffmann-La Roche Ltd.
  • 17.13. GenScript Biotech Corporation
  • 17.14. Illumina, Inc.
  • 17.15. Intellia Therapeutics, Inc.
  • 17.16. Merck KGaA
  • 17.17. Myriad Genetics, Inc.
  • 17.18. PerkinElmer, Inc.
  • 17.19. QIAGEN N.V.
  • 17.20. Sangamo Therapeutics, Inc.
  • 17.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENETIC ANALYSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENETIC ANALYSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY GENETIC DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY GENETIC DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY GENETIC DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS GENETIC ANALYSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA GENETIC ANALYSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GCC GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. GCC GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. GCC GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. GCC GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. G7 GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. G7 GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. G7 GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. G7 GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. G7 GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NATO GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. NATO GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NATO GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. NATO GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)